Adagio Medical’s ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference

Published: 2026-04-16 08:03:09 ET ADGM

Use of ULTA Across Broad Spectrum of Ventricular Tachycardias to be Highlighted in Multiple Scientific Presentations, Including Late-Breaking Clinical Trial Session

Published on 04/16/2026 at 08:03 am EDT

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that its Ultra-low Temperature Ablation technologies (ULTA) for the treatment of scar-related ventricular tachycardia will be featured in several presentations at the Heart Rhythm Society's 47th Annual Scientific Sessions – Heart Rhythm 2026 conference, to be held from Thursday, April 23 to Sunday, April 26, 2026, in Chicago, Illinois at the McCormick Place Convention Center.

In addition to its booth and technology suite, Adagio’s ULTA technologies will be featured in several events and presentations:

Friday, April 24, 2026

Saturday, April 25, 2026

Sunday, April 26, 2026: Late-Breaking Clinical Trial Presentation

About Adagio Medical Holdings, Inc.

Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Ablation (ULTA, formerly known as ULTC) technology. ULTA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue, all through an endocardial approach. The Company is currently focused on the treatment of ventricular arrhythmias with its purpose-built vCLAS™ Cryoablation System, which is CE Marked and is currently under evaluation in the Company’s FULCRUM-VT U.S. Pivotal IDE Trial.

About FULCRUM VT

FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label, single-arm trial, which has fully enrolled 209 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory VT in accordance with current treatment guidelines. The results of the study will be used to apply for U.S. Food and Drug Administration (FDA) premarket approval (PMA) for Adagio’s vCLAS™ Cryoablation System, potentially leading to the broadest industry indication for purely endocardial ablation of scar-mediated VT.

Adagio’s vCLAS™ Cryoablation System is commercially available for the treatment of monomorphic VT in Europe and select other geographies but is limited to investigational use in the United States.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260416240050/en/